View the latest content on Obesity & NASH Drug Development and other events of the CVRM & Liver Series
NEW!
An exclusive Interview with:
Ginnie Yang, Vice President of Inflammation, Exploratory Pathobiology & Tissue Repair, Bayer
An exclusive FDA presentation by:
Dr Frank A. Anania, Acting Clinical Team Leader, Division of Gastroenterology and Inborn Error Products, FDA
Laurent Fischer, MD Senior Vice President, Liver Therapeutic Area Head, ALLERGAN PLC
ON THE THRESHOLD OF A THERAPEUTIC MILESTONE
Peter G. Traber, MD Partner, Alacrita Consulting : NASH Now: Therapeutic Targets & the Competitive Clinical Trial Landscape
Brent A. Neuschwander-Tetri, Professor of Internal Medicine - Saint Louis University. : Many Paths to NASH- Many Targets for Treatment
Yury Popov, MD PhD, Beth Israel Deaconess Medical Center, Harvard Medical School: Understanding Hepatocellular Carcinoma as an Extension of NASH: practical implications for drug development
Liat Hayardeny, Chief Scientific Officer, Galmed Pharmaceuticals: Aramchol Phase II b Results & Phase III Outlook
Greg Everson, Chief Executive Officer & Manager, HepQuant: Tests of the Liver’s Function and Physiology to Assess Liver Disease and Monitor Treatment Effects
Nikolai Naoumov, MD PhD, Exucutive Director - Hepatology Science& Innovation, Global Drug Development Novartis Pharma: Which Mechanisms of Action to Combine to Address NASH
Eric Lefebvre, Chief Medical Officer - Pliant Therapeutics Inc. : Disruption of TGF β activation by an α V β 1 integrin inhibitor reduces liver fibrosis in human NASH liver slices and mice
Targeting multiple pathways in NASH - clinical perspectives for combination therapies | Nikolai Naoumov
Molecular MR Imaging of Oxidized Collagen to Monitor Active Fibrogenesis in Preclinical Models of NASH | Bryan Fuchs
Evaluating Progression Towards Industry Standard In Vitro Models of NAFLD/NASH
